2010
DOI: 10.1093/bja/aep340
|View full text |Cite
|
Sign up to set email alerts
|

Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study †

Abstract: Large differences in the PKs of sugammadex and rocuronium between patients with renal failure and healthy controls were observed. The effect of renal impairment on the PK variables of rocuronium was less than with sugammadex. Urinary excretion of both drugs was reduced in renal patients.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
126
0
3

Year Published

2011
2011
2024
2024

Publication Types

Select...
4
2
2

Relationship

0
8

Authors

Journals

citations
Cited by 133 publications
(131 citation statements)
references
References 18 publications
2
126
0
3
Order By: Relevance
“…12 The distribution of sugammadex is restricted to the intravascular space due to the low volume of distribution at steady state estimated at 0.16 LÁkg -1 . 13 Thus, as is the case for non-depolarizing muscle relaxants, it might be relevant to determine the dose of sugammadex based on the ideal body weight and not on the actual body weight. 14 The affinity of sugammadex for rocuronium is high, so unbinding of sugammadex-rocuronium complexes is unlikely.…”
Section: Discussionmentioning
confidence: 99%
“…12 The distribution of sugammadex is restricted to the intravascular space due to the low volume of distribution at steady state estimated at 0.16 LÁkg -1 . 13 Thus, as is the case for non-depolarizing muscle relaxants, it might be relevant to determine the dose of sugammadex based on the ideal body weight and not on the actual body weight. 14 The affinity of sugammadex for rocuronium is high, so unbinding of sugammadex-rocuronium complexes is unlikely.…”
Section: Discussionmentioning
confidence: 99%
“…Therefore, at this time standard dosing continues to be based on weight and train of four twitches as outlined in the Hepatic metabolism is responsible for rocuronium and vecuronium clearance; renal clearance regulates the sugammadex-NMBA complex elimination. 10,[18][19][20][21][22][23][24] In healthy kidneys with a glomerular filtration rate (GFR) of 75-120 ml/min, 70% of the dose is excreted in six hours, and 80-90% in 24 hours. 21,25,26 In renal failure, with GFR <30ml/min, only 29% of the dose administered is cleared by 72 hours.…”
Section: Dosingmentioning
confidence: 99%
“…21,25,26 In renal failure, with GFR <30ml/min, only 29% of the dose administered is cleared by 72 hours. 24 The use of high-flux dialysis removes the bound sugammadex, but at this time sugammadex administration is not recommended for patients with severe renal dysfunction. 16,18,23,24 clinicAl ApplicAtions Sugammadex has many advantages when compared to the administration of neostigmine or no reversal agent at all.…”
Section: Dosingmentioning
confidence: 99%
“…The administration must be modified in patients with renal diseases, adjusting the dosage to the actual renal function. The security in dyalazed patients is limited and the use is not recommended in severe renal failure (creatinine clearance < 30 ml/min) (Abrishami et al, 2010;Della Rocca G et al, 2009;Duvaldestin P et al, 2009;Khuenl-Brady KS et al, 2010;Lee C et al, 2009;McDonagh DL et al, 2011;Plaud B et al, 2009;Schaller SJ et al, 2010;Staals LM et al, 2010;White PF et al,2009) …”
Section: Sugammadexmentioning
confidence: 99%